Login
$EYPT
$0.29 -$0.02 (5.95%) After hours

$EYPT 8-K/A SEC Filings

Filed On Filing
29 Jul 2025 8-K/A: Other Events

LUCIA pivotal Phase 3 trial enrolled and randomized over 400 patients in seven months, demonstrating continued strong enthusiasm for the DURAVYU pivotal program across the global retinal community –

23 May 2023 8-K/A: Financial Statements and Exhibits

On May 17, 2023 (the “Closing Date”), EyePoint Pharmaceuticals, Inc. (the “Company”) entered into a product rights agreement (the “Product Rights Agreement”) with Alimera Sciences, Inc. (“Alimera”) to grant to Alimera an exclusive (even ...

12 Jan 2022 8-K/A: Other Events

1 | EYEPOINT PHARMACEUTICALS Delivering Innovation to the Eye Investor Presentation January 2022 Exhibit 99.1

16 Jan 2020 8-K/A: Other Events

INVESTOR PRESENTATION JANUARY 2020 NASDAQ: EYPT Exhibit 99.1

09 Sep 2019 8-K/A: Submission of Matters to a Vote of Security Holders

The Company has determined, in light of and consistent with the advisory vote of the Company’s stockholders as to the preferred frequency of stockholder advisory votes on the compensation of the Company’s named executive officers, to inc...

11 Jun 2018 8-K/A: Completion of Acquisition or Disposition of Assets; Other Events

We have audited the accompanying financial statements of Icon Bioscience, Inc. (the Company), which comprise the balance sheets as of December 31, 2017 and 2016, and the related statements of operations, stockholders’ equity (deficit) an...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support